WHO sends Panacea to remediation

It's time to revise the revenue projections at Panacea Biotech. The World Health Organization, following a late June manufacturing plant inspection, has removed three of the drugmaker's combination vaccines from its pre-qualification list, meaning the WHO won't buy its drugs due to the sub-par manufacturing practices observed.

Inspectors found quality management deficiencies at Panacea's vaccine plant near Punjab, India. The vaccines in question include combinations of diphtheria, pertussis, tetanus, Hepatitis B and Hib B. Their final disposition awaits a decision on their acceptability for distribution by the United Nations, which will be made by a WHO-convened committee.

Panacea said the company has begun corrective measures and expects to soon apply for re-listing of the drugs. There are reportedly no quality issues with the vaccines already in the market.

The news is a blow to the vaccine industry in India, which Unicef named the low-cost supplier in most categories following a survey of supplier pricing data that the organization made public for the first time in June. Findings revealed nearly a $1 spread in the 2010 price for one vaccine sourced from 5 suppliers.

- here's the story


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.